After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. Read more here: https://lnkd.in/e3PX9kcZ
Community Liver Alliance
健康与健身服务
Pittsburgh，Pennsylvania 625 位关注者
Mission in Motion, The Community Liver Alliance is dedicated to supporting the community through liver disease awareness
关于我们
Headquartered in Pittsburgh, the Community Liver Alliance has grown to have a national presence while still holding true to a mission to invest in local communities and give voice to patients and providers. The CLA is dedicated to supporting the community through liver disease awareness, prevention, education, advocacy and research. Supported by a network of patients, caregivers, health care professionals and community leaders, CLA develops and runs educational workshops, coordinates support groups, facilities linkage to medical care and provides education to health care professionals, patients and caregivers.
- 网站
-
https://www.communityliveralliance.org
Community Liver Alliance的外部链接
- 所属行业
- 健康与健身服务
- 规模
- 2-10 人
- 总部
- Pittsburgh，Pennsylvania
- 类型
- 非营利机构
地点
-
主要
获取路线
100 W Station Square Dr
Suite 212
US，Pennsylvania，Pittsburgh，15219
Community Liver Alliance员工
动态
-
Advances in the clinical management of cholestasis have focused on mitochondrial dysfunction and bile acid metabolism. This review discusses several novel therapeutic agents that have shown promise in treating cholestasis by modulating these pathways. https://lnkd.in/eJU9aHAw
Mitochondria at the crossroads of cholestatic liver injury: Targeting novel therapeutic avenues
eurekalert.org
-
Madrigal Pharmaceuticals to Present Multiple Rezdiffra? (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting. https://lnkd.in/eJED8Z-h
Madrigal Pharmaceuticals to Present Multiple Rezdiffra? (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting? | Madrigal Pharmaceuticals.
ir.madrigalpharma.com
-
Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed. https://lnkd.in/gzeCAfge
Pemvidutide linked to ‘rapid and potent’ reduction in liver fat in MASLD at 12 weeks
healio.com
-
The U.S. Food and Drug Administration approved Gilead Sciences' (GILD.O), opens new tab liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year. https://lnkd.in/eGS57VFM
Gilead gets US FDA approval for inflammatory liver disease drug
reuters.com
-
A study showed that Genetic mutation associated with MASLD, a form of fatty liver disease, results in an abnormal buildup of fat inside lab-grown human liver cells, a discovery that could help researchers target treatments to reduce fat accumulation. https://lnkd.in/eXS7fC7W
-
Join 340B's Webinar: What to Expect Next on 340B and Drug Pricing in Washington, D.C. on December 3, 12:00-1:00 p.m. ET. https://lnkd.in/dAE_SaGi
Subscribe - 340B Report
https://340breport.com
-
Please join the Hepatitis B Foundation for an engaging Virtual B Informed Patient Conference—a platform connecting those with lived experience, health care providers and researchers for an in-depth discussion on hepatitis B and hepatitis D. https://lnkd.in/ea8Fn-Sn
Welcome! You are invited to join a webinar: B Informed Virtual Patient Conference. After registering, you will receive a confirmation email about joining the webinar.
us02web.zoom.us
-
Yale's new research looked at whether ongoing liver cancer screening for individuals who achieved hepatitis C cure improves their overall survival rates. https://lnkd.in/erAZ_gs6